Members |
targetComponentId |
Trifluoperazine hydrochlorid 5mg tablet |
Product containing precisely trifluoperazine (as trifluoperazine hydrochloride) 5 milligram/1 each conventional release oral tablet (clinical drug) |
trifluoperazinhydroklorid 10 mg/ml, lösning |
Trifluoperazine 10 mg/mL oral solution |
trigemino-sympatiskt syndrom |
Paratrigeminal syndrome |
trihexyfenidylhydroklorid 5 mg, kapsel med modifierad frisättning |
Product containing only trihexyphenidyl in oral dose form (medicinal product form) |
trihexyfenidylhydroklorid 5 mg, depåkapsel |
Product containing only trihexyphenidyl in oral dose form (medicinal product form) |
extrakt specifikt för bensentrikarboxylsyraanhydrid |
Trimellitic acid |
trimestrar |
Maternal antenatal period |
Trimethobenzamide 100mg/mL |
Trimethobenzamide hydrochloride 100 mg/mL solution for injection |
Trimethobenzamide hydrochlor 100mg/mL solution |
Trimethobenzamide hydrochloride 100 mg/mL solution for injection |
trimetobensamidhydroklorid 100 mg/ml, intramuskulär lösning |
Trimethobenzamide hydrochloride 100 mg/mL solution for injection |
trimetobensamidhydroklorid 100 mg |
Product containing precisely trimethobenzamide (as trimethobenzamide hydrochloride) 100 milligram/1 each conventional release rectal suppository (clinical drug) |
Trimethobenzamide hydrochloride 100mg/mL bar |
Product containing precisely trimethobenzamide (as trimethobenzamide hydrochloride) 100 milligram/1 each conventional release rectal suppository (clinical drug) |
trimetobensamidhydroklorid 100 mg/ml, injektionsvätska, lösning, ampull |
Trimethobenzamide hydrochloride 100 mg/mL solution for injection |
trimetobensamidhydroklorid 200 mg, suppositorium |
Product containing precisely trimethobenzamide (as trimethobenzamide hydrochloride) 200 milligram/1 each conventional release rectal suppository (clinical drug) |
trotyl |
Trinitrotoluene (substance) |
trifalangeala tummar med missbildning av nagel |
Deafness, onychodystrophy, osteodystrophy, intellectual disability syndrome (disorder) |
Triphosphoric monoester hydrolase |
Triphosphoric monoester hydrolase |
triprolidinhydroklorid 100 % |
Product containing triprolidine (medicinal product) |
triptorelinpamoat 11,25 mg/flaska, frystorkat pulver till injektionsvätska, suspension |
Triptorelin only product in parenteral dose form |
triptorelinpamoat 11,25 mg, pulver i flaska |
Triptorelin only product in parenteral dose form |
triptorelinpamoat 3,75 mg/flaska, frystorkat pulver till injektionsvätska, suspension |
Triptorelin only product in parenteral dose form |
triptorelinpamoat 3,75 mg, pulver i flaska |
Triptorelin only product in parenteral dose form |
trinatriumedetatallergi |
Allergy to edetate (finding) |
Tritiarchium |
Tritirachium |
Tritiarchium oryzae |
Tritirachium oryzae |
Trophic ulcer |
Neurogenic ulcer |
tropikamid 0,5 %, ögondroppar |
Product containing precisely tropicamide 5 milligram/1 milliliter conventional release eye drops (clinical drug) |
tropikamid 0,5 %, ögondroppar för engångsbruk |
Product containing precisely tropicamide 5 milligram/1 milliliter conventional release eye drops (clinical drug) |
tropikamid 1 %, ögondroppar |
Product containing precisely tropicamide 10 milligram/1 milliliter conventional release eye drops (clinical drug) |
tropikamid 1 %, ögondroppar för engångsbruk |
Product containing precisely tropicamide 10 milligram/1 milliliter conventional release eye drops (clinical drug) |
öring, livsmedel |
Trout (substance) |
True bug |
Order Hemiptera (organism) |
True histiocytic lymphoma |
Histiocytic sarcoma |
bållambå |
Flap (substance) |
trypanblått 0,06 %, lösning för oftalmiskt bruk |
Trypan blue stain only product |
trypanblått 1,5 mg/ml, lösning för oftalmiskt bruk |
Trypan blue stain only product |
Tryptase |
Tryptase |
Tsukamurella wratislaviensis |
Rhodococcus wratislaviensis (organism) |
tubarabort |
Miscarriage of tubal ectopic pregnancy |
tubal-cornual placenta |
Cornual placenta accreta |
PPD-tuberkulin 100 000 enheter/ml, injektionsvätska, lösning, ampull 1 ml |
Product containing precisely tuberculin purified protein derivative 100000 unit/1 milliliter conventional release solution for injection (clinical drug) |
PPD-tuberkulin 1:10 000 (10 enheter/ml), injektionsvätska, lösning, ampull 1 ml |
Product containing precisely tuberculin purified protein derivative 10 unit/1 milliliter conventional release solution for injection (clinical drug) |
PPD-tuberkulin 1:100 (1 000 enheter/ml), injektionsvätska, lösning, ampull 1 ml |
Tuberculin purified protein derivative 1000 unit/mL solution for injection |
PPD-tuberkulin 1:1 000 (100 enheter/ml), injektionsvätska, lösning, ampull 1 ml |
Product containing precisely tuberculin purified protein derivative 100 unit/1 milliliter conventional release solution for injection (clinical drug) |
tuberkulin, renat protein 1 enhet/ml, injektionsvätska, lösning, flaska |
Tuberculin purified protein derivative 50 unit/mL solution for injection |
Tuberculosis of cervical lymph nodes |
Cervical tuberculous lymphadenitis |
Tuberculosis of other female genital organs |
Tuberculosis of female genital organs |
Tuberculosis of other specified bone |
Tuberculosis of bone |
Tuberculosis of other urinary organs (disorder) |
Primary progressive tuberculosis |
Tuberculosis of other urinary organs |
Tuberculosis of urinary organs |
Tuberculosis of peritoneum |
Tuberculous peritonitis |
Tuberculous |
Tuberculous (qualifier value) |
Tuberculous spondylitis |
Tuberculosis of vertebral column |
tubulärt adenom, kategori |
Benign tubular adenoma (morphologic abnormality) |
tubulärt adenom |
Benign tubular adenoma (morphologic abnormality) |
tumör grad GB |
GB |
tumörstadium T1a |
cT1a |
tumörstadium T1a1 |
American Joint Committee on Cancer cT1a1 (qualifier value) |
tumörstadium T1a2 |
American Joint Committee on Cancer cT1a2 (qualifier value) |
tumörstadium T1b |
cT1b |
tumörstadium T1b1 |
American Joint Committee on Cancer cT1b1 (qualifier value) |
tumörstadium T1b2 |
American Joint Committee on Cancer cT1b2 (qualifier value) |
tumörstadium T1c |
American Joint Committee on Cancer cT1c (qualifier value) |
tumörstadium T1mic |
cT1mi |
tumörstadium T2a |
cT2a |
tumörstadium T2b |
American Joint Committee on Cancer cT2b (qualifier value) |
tumörstadium T2c |
American Joint Committee on Cancer cT2c (qualifier value) |
tumörstadium T3a |
American Joint Committee on Cancer cT3a (qualifier value) |
tumörstadium T3b |
cT3b |
tumörstadium T3bi |
cT3b |
tumörstadium T3bii |
cT3b |
tumörstadium T3c |
American Joint Committee on Cancer cT3c (qualifier value) |
tumörstadium T4a |
American Joint Committee on Cancer cT4a (qualifier value) |
tumörstadium T4b |
cT4b |
tumörstadium T4c |
American Joint Committee on Cancer cT4c (qualifier value) |
tumörstadium T4d |
American Joint Committee on Cancer cT4d (qualifier value) |
tumörstadium Ta |
American Joint Committee on Cancer cTa (qualifier value) |
tumörstadium Tis pd |
cTis |
tumörstadium Tis pu |
cTis |
TNM-stadieindelning av kolon- och rektaltumörer |
American Joint Committee on Cancer allowable value |
TNM-stadieindelning av Hodgkins sjukdom |
American Joint Committee on Cancer allowable value |
TNM-stadieindelning av prostatatumörer |
American Joint Committee on Cancer allowable value |
TNM-stadieindelning av tunntarmstumörer |
American Joint Committee on Cancer allowable value |
TNM-stadieindelning av Wilms tumör |
American Joint Committee on Cancer allowable value |
TNM-stadieindelning av tumörer i ampulla hepatopancreatica |
American Joint Committee on Cancer allowable value |
TNM-stadieindelning av tumörer i analkanalen |
American Joint Committee on Cancer allowable value |
TNM-stadieindelning av benvävnads- och mjukdelstumörer |
American Joint Committee on Cancer allowable value |
TNM-stadieindelning av benvävnadstumörer |
American Joint Committee on Cancer allowable value |
TNM-stadieindelning av hjärntumörer |
American Joint Committee on Cancer allowable value |
TNM-stadieindelning av brösttumörer |
American Joint Committee on Cancer allowable value |
TNM-stadieindelning av konjunktivalt karcinom |
American Joint Committee on Cancer allowable value |
TNM-stadieindelning av ögonlockscancer |
American Joint Committee on Cancer allowable value |
TNM-stadieindelning av hudkarcinom |
American Joint Committee on Cancer allowable value |
TNM-stadieindelning av tumörer i livmoderhals |
American Joint Committee on Cancer allowable value |
TNM-stadieindelning av kolontumörer |
American Joint Committee on Cancer allowable value |
TNM-stadieindelning av tumörer i corpus uteri |
American Joint Committee on Cancer allowable value |
TNM-stadieindelning av tumörer i matspjälkningssystemet |
American Joint Committee on Cancer allowable value |
TNM-stadieindelning av esofagustumörer |
American Joint Committee on Cancer allowable value |
TNM-stadieindelning av tumörer i etmoidalsinus |
American Joint Committee on Cancer allowable value |
TNM-stadieindelning av tumörer i extrahepatiska gallgångar |
American Joint Committee on Cancer allowable value |
TNM-stadieindelning av äggledartumörer |
American Joint Committee on Cancer allowable value |